1、Mao W, Wang K, Zhang H, Lu H, Sun S, Tian C, WuZ, Wu J, Xu B, Xu H, Peng B, Chen M. Sarcopenia as a poor prognostic indicatorfor renal cell carcinoma patients undergoing nephrectomy in China: Amulticenter study. Clin Transl Med. 2021 Jan;11(1):e270.
2、Mao W, Fu Z, Wang K, Wu J, Xu B, Chen M.Prognostic nomogram for patients with lung metastatic renal cell carcinoma: aSEER-based study. Ann Palliat Med. 2021 Mar;10(3):2791-2804.
3、Mao W, Hu Q, Chen S, Chen Y, Luo M, Zhang Z, GengJ, Wu J, Xu B, Chen M. Polyfluoroalkyl chemicals and the risk of kidney stonesin US adults: A population-based study. Ecotoxicol Environ Saf. 2021 Jan15;208:111497.
4、Mao W, Zhang H, Xu Z, Geng J, Zhang Z, Wu J, XuB, Chen M. Relationship between urine specific gravity and the prevalence rateof kidney stone. Transl Androl Urol. 2021 Jan;10(1):184-194.
5、Mao W, Zhang H, Xu Z, Geng J, Zhang Z, Wu J, XuB, Chen M. Relationship between urine specific gravity and the prevalence rateof kidney stone. Transl Androl Urol. 2021 Jan;10(1):184-194.
6、Mao W, Wu J, Zhang Z, Xu Z, Xu B, Chen M.Neutrophil-lymphocyte ratio acts as a novel diagnostic biomarker for kidneystone prevalence and number of stones passed. Transl Androl Urol. 2021Jan;10(1):77-86.
7、Bin X, Yong S, Kong QF, Zhao S, Zhang GY, Wu JP, Chen SQ, Zhu WD,Pan KH, Du ML, Chen M. Diagnostic Performance of PET/CT Using 18F-FACBC inProstate Cancer: A Meta-Analysis. Front Oncol. 2020 Jan 10;9:1438.
8、Liu C, Chen L, You Z, Wu Y, Wang C, Zhang G, Xu B, Chen M.Association between lncRNA H19 polymorphisms and cancer susceptibility based ona meta-analysis from 25 studies. Gene. 2020 Mar 1;729:144317.
9、Mao W, Ma B, Wang K, Wu J, Xu B, Geng J, Zhang H, Chen M.Sarcopenia predicts prognosis of bladder cancer patients after radicalcystectomy: A study based on the Chinese population. Clin Transl Med. 2020Jun;10(2):e105.
10、Guan H, Peng R, Fang F, Mao L, Chen Z, Yang S, Dai C, Wu H, WangC, Feng N, Xu B, Chen M. Tumor-associated macrophages promote prostate cancerprogression via exosome-mediated miR-95 transfer. J Cell Physiol. 2020Dec;235(12):9729-9742.
11、Guan H, Peng R, Mao L, Fang F, Xu B, Chen M. Injured tubularepithelial cells activate fibroblasts to promote kidney fibrosis throughmiR-150-containing exosomes. Exp Cell Res. 2020 Jul 15;392(2):112007.
12、Shi N, Zu F, Shan Y, Chen S, Xu B, Du M, Chen M. The value ofrenal score in both determining surgical strategies and predicting complicationsfor renal cell carcinoma: A systematic review and meta-analysis. Cancer Med.2020 Jun;9(11):3944-3953.
13、Xu B, Wang C, Wang YL, Chen SQ, Wu JP, Zhu WD, Wang CY, Guan H,Guan C, You ZH, Chen M. miR-143 inhibits renal cell carcinoma cells metastaticpotential by suppressing ABL2. Kaohsiung J Med Sci. 2020 Aug;36(8):592-598.
14、Pan KH, Jian L, Chen WJ, Nikzad AA, Kong FQ, Bin X, Wang YL, ChenM. Diagnostic Performance of Contrast-Enhanced Ultrasound in Renal Cancer: AMeta-Analysis. Front Oncol. 2020 Nov 18;10:586949.
15、Wu Y, Jing J, Wang J, Xu B, Du M, Chen M. Robotic-AssistedSentinel Lymph Node Mapping With Indocyanine Green in Pelvic Malignancies: ASystematic Review and Meta-Analysis. Front Oncol. 2019 Jul 2;9:585.
16、Guan H, You Z, Wang C, Fang F, Peng R, Mao L, Xu B, Chen M.MicroRNA-200a suppresses prostate cancer progression through BRD4/AR signalingpathway. Cancer Med. 2019 Apr;8(4):1474-1485.
17、Zhang N, Wang X, Wang C, Chen S, Wu J, Zhang G, Zhu W, Liu J, XuB, Du M, Chen M. Diagnostic Accuracy of Multi-Parametric Magnetic ResonanceImaging for Tumor Staging of Bladder Cancer: Meta-Analysis. Front Oncol. 2019Oct 4;9:981.
18、Xu B, Lu X, Zhao Y, Liu C, Huang X, Chen S, Zhu W, Zhang L, ChenM. MicroRNA-135a induces prostate cancer cell apoptosis via inhibition ofSTAT6. Oncol Lett. 2019 Feb;17(2):1889-1895.
19、Zhang M, Wang R, Wu Y, Jing J, Chen S, Zhang G, Xu B, Liu C, ChenM. Micro-Ultrasound Imaging for Accuracy of Diagnosis in Clinically SignificantProstate Cancer: A Meta-Analysis. Front Oncol. 2019 Dec 10;9:1368.
20、You Z, Liu C, Wang C, Ling Z, Wang Y, Wang Y, Zhang M, Chen S, XuB, Guan H, Chen M. LncRNA CCAT1 Promotes Prostate Cancer Cell Proliferation byInteracting with DDX5 and MIR-28-5P. Mol Cancer Ther. 2019 Dec;18(12):2469-2479.
21、Ling Z, You Z, Hu L, Zhang L, Wang Y, Zhang M, Zhang G, Chen S, XuB, Chen M. Effects of four single nucleotide polymorphisms of EZH2 oncancer risk: a systematic review and meta-analysis. Onco Targets Ther. 2018 Feb16;11:851-865.
22、Wang X, Wang W, Zhang Q, Gu D, Zhang K, Ge Y, Chu H, Du M, Xu B,Wang M, Lv X, Zhang Z, Yuan L, Gong W. Tagging SNPs in the HOTAIR gene areassociated with bladder cancer risk in a Chinese population. Gene. 2018 Jul20;664:22-26.
23、Ling Z, Guan H, You Z, Wang C, Hu L, Zhang L, Wang Y, Chen S, Xu B,Chen M. Aloperine executes antitumor effects through the induction of apoptosisand cell cycle arrest in prostate cancer in vitro and in vivo. Onco TargetsTher. 2018 May 11;11:2735-2743.
24、Huang Y, Tao T, Liu C, Guan H, Zhang G, Ling Z, Zhang L, Lu K,Chen S, Xu B, Chen M. Upregulation of miR-146a by YY1 depletion correlates withdelayed progression of prostate cancer. Int J Oncol. 2017 Feb;50(2):421-431.
25、Guan H, Liu C, Fang F, Huang Y, Tao T, Ling Z, You Z, Han X, ChenS, Xu B, Chen M. MicroRNA-744 promotes prostate cancer progression throughaberrantly activating Wnt/β-catenin signaling. Oncotarget. 2017 Feb28;8(9):14693-14707.
26、Ling Z, Wang X, Tao T, Zhang L, Guan H, You Z, Lu K, Zhang G, ChenS, Wu J, Qian J, Liu H, Xu B, Chen M. Involvement of aberrantly activatedHOTAIR/EZH2/miR-193a feedback loop in progression of prostate cancer. J ExpClin Cancer Res. 2017 Nov 15;36(1):159.
27、Zhang X, Tao T, Liu C, Guan H, Huang Y, Xu B, Chen M.Downregulation of miR-195 promotes prostate cancer progression by targetingHMGA1. Oncol Rep. 2016 Jul;36(1):376-82.
28、Zhang L, Zhang XW, Liu CH, Lu K, Huang YQ, Wang YD, Xing L, ZhangLJ, Liu N, Jiang H, Sun C, Yang Y, Chen SQ, Chen M, Xu B. miRNA-30a functionsas a tumor suppressor by downregulating cyclin E2 expression in castration-resistantprostate cancer. Mol Med Rep. 2016 Sep;14(3):2077-84.
29、Xu B, Tao T, Wang Y, Fang F, Huang Y, Chen S, Zhu W, Chen M.hsa-miR-135a-1 inhibits prostate cancer cell growth and migration by targetingEGFR. Tumour Biol. 2016 Oct;37(10):14141-14151.
30、Wang J, Yang Y, Chen M, Tao T, Liu C, Huang Y, Guan H, Han X, XuB. Laparoscopic pyelolithotomy versus percutaneous nephrolithotomy fortreatment of large renal pelvic calculi (diameter >2 cm): a meta-analysis.Acta Chir Belg. 2016 Dec;116(6):346-356.
31、Xu B, Tao T, Wang Y, Fang F, Huang Y, Chen S, Zhu W, Chen M. hsa-miR-135a-1inhibits prostate cancer cell growth and migration by targeting EGFR.TumourBiol. 2016 Oct;37(10):14141-14151. Epub 2016 Aug 14.3.65
32、Liu D, Tao T, Xu B, Chen S, Liu C, Zhang L, Lu K, Huang Y, JiangL, Zhang X, Huang X, Zhang L, Han C, Chen M. MiR-361-5pacts as a tumor suppressor in prostate cancer by targeting signal transducerand activator of transcription-6(STAT6).BiochemBiophys Res Commun. 2014 Feb 28;445(1):151-6. doi:10.1016/j.bbrc.2014.01.140. Epub 2014 Jan 31
33、Xu B, Huang Y, Niu X, Tao T, Jiang L, Tong N, Chen S, Liu N, ZhuW, Chen M. Hsa-miR-146a-5p modulates androgen-independent prostatecancer cells apoptosis by targeting ROCK1.Prostate.2015 Dec;75(16):1896-903.
34、Liu C, Tao T, Xu B, Lu K, Zhang L, Jiang L, Chen S, Liu D, ZhangX, Cao N, Chen M. BTG1 potentiates apoptosis and suppresses proliferation inrenal cell carcinoma by interacting with PRMT1.OncolLett. 2015 Aug;10(2):619-624. Epub 2015 May 29
35、Chen S, Xu B, Liu N, Jiang H, Zhang X, Yang Y, Liu J, Sha G, ZhuW, Chen M. Improved effectiveness and safety of flexible ureteroscopyfor renal calculi (<2 cm): A retrospective study.Can Urol Assoc J. 2015 May-Jun;9(5-6):E273-7.
36、Zhang L, Xu B, Wang Y, Liu C, Lu K, Huang Y, Liu N, Zhang X, ChenS, Chen M. Advanced renal cell carcinoma associated with vonHippel-Lindau disease: A case report and review of the literature.Oncol Lett. 2015 Aug;10(2):1087-1090. Epub 2015 May 271.664
37、Tong N, Xu B, Shi D, Du M, Li X, Sheng X, Wang M, Chu H, Fang Y,Li J, Wu D, Zhang Z. Hsa-miR-196a2 polymorphism increases the risk of acutelymphoblastic leukemia in Chinese children.MutatRes. 2014 Jan;759:16-21.
38、Zhang X, Fang J, Xu B, Zhang S, Su S, Song Z, Deng Y, Wang H, ZhaoD, Niu X, Wang Z. Correlation of epididymal protease inhibitor andfibronectin in human semen.PLoS One. 2013Dec 16;8(12):e82600.
39、Chen S, Xu B, Liu J, Ren Q, Hu X, Yang Y, Zhang X, Chen M. Retroperitoneallaparoscopic reconstruction for retrocaval ureter: experience and literaturereview.J Endourol. 2012 Sep;26(9):1147-52.
40、Xu B, Lu X, Zhao Y, Liu C, Huang X, Chen S, Zhu W, Zhang L, ChenM. MicroRNA-135a induces prostate cancer cell apoptosis viainhibition of STAT6.
Oncol Lett. 2019Feb;17(2):1889-1895.
41、Chen M, Xu B, Liu N, Jiang H, Wang Y, Yang Y, Zhang X, Sun C, LiuJ, Zhu W, Chen S. Precise control of caval and hepatic vessels: Surgicaltechnique to treat level III caval thrombus concomitant to renal cellcarcinoma.Can Urol Assoc J. 2015Nov-Dec;9(11-12):E808-13.
42、Xu B, Wang N, Wang X, Tong N, Shao N, Tao J, Li P, Niu X, Feng N,Zhang L, Hua L, Wang Z, Chen M. MiR-146asuppresses tumor growth and progression by targeting EGFR pathway and in ap-ERK-dependent manner in castration-resistant prostate cancer.Prostate. 2012 Aug 1;72(11):1171-8.
43、Liu D, Xu B, Chen S, Yang Y, Zhang X, Liu J, Lu K, Zhang L, Liu C,Zhao Y, Jiang H, Liu N, Chen M. Longnon-coding RNAs and prostate cancer.J NanosciNanotechnol. 2013 May;13(5):3186-941.354
44、Xu B, Tong N, Chen SQ, Hua LX, Wang ZJ, Zhang ZD, Chen M. FGFR4Gly388Arg polymorphism contributes to prostate cancer development andprogression: a meta-analysis of 2618 cases and 2305 controls.BMC Cancer. 2011 Feb 24;11:84.
45、Tao T, Liu D, Liu C, Xu B, Chen S, Yin Y, Ang L, Huang Y, Zhang X,Chen M. Autoregulatory feedback loop of EZH2/miR-200c/E2F3 as adriving force for prostate cancer development.BiochimBiophys Acta. 2014 Sep;1839(9):858-65.
46、Zhang L, Xul B, Chen S, Lu K, Liu C, Wang Y, Zhao Y, Zhang X, LiuD, Chen M. The complex roles of microRNAs inthe metastasis of renal cell carcinoma.J NanosciNanotechnol. 2013 May;13(5):3195-203. Review
47、Xu B1, Feng NH, Li PC, Tao J, Wu D, Zhang ZD, Tong N, Wang JF, Song NH, Zhang W, Hua LX, Wu HF. Afunctional polymorphism in Pre-miR-146a gene is associated withprostate cancer risk and mature miR-146a expression invivo.Prostate. 2010 Apr 1;70(5):467-72.
48、Xu B1, Wang J, Tong N, Mi Y, Min Z, Tao J, Li P, Cheng G, Li J, Wang M, Tang J, Song N, Zhang Z, Zhang W, Wu H, Hua L, Feng N. A functional polymorphism in MSMBgene promoter is associated with prostate cancer risk and serum MSMBexpression.Prostate.2010 Jul 1;70(10):1146-52.
49、Xu B, Mi YY, Min ZC, Cheng G, Tong N, Tao J, Li PC, Wang ML, TangJL, Zhang ZD, Song NH, Zhang W, Wu HF, Feng NH, Hua LX.p53codon72increasedbiochemicalrecurrenceriskafterradicalprostatectomyin asouthernChinesepopulation.Urol Int. 2010;85(4):401-5.
50、Bin Xua , Zheng Xuc, Gong Chenga, Zhi-Chao Mina, Yuanyuan Mia,Zhi-zhong Zhangb, Jun Taoa, Peng-Chao Lia, Mei-Lin Wangb, Jia-Lin Tangb,Zheng-Dong Zhangb, Wei Zhanga, Hong-Fei Wud, Ning-Han Fenga, Li-Xin Huaa, Associationbetween polymorphisms of TP53 and MDM2 and prostate cancer risk in southernChinese.Cancer Genetics and Cytogenetics 202 (2010) 76e8
51、Bin Xu ,Xiao-Bing Niu, Zi-Dun Wang, Wei Cheng , Na Tong, Yuan-Yuan Mi , Zhi-Chao Min , Jun Tao , Peng-Chao Li , Wei Zhang, Hong-Fei Wu ,
Zheng-Dong Zhang , Zeng-Jun Wang, Li-Xin Hua, Ning-Han Feng, Xin-Ru Wang. IL-6 -174G>C polymorphism andcancer risk: a meta-analysis involving 29,377 cases and 37,739 controls.MolBiol Rep.2011Apr;38(4):2589-96.
52、Xu B,Min Z,Cheng G,Mi Y,Tong N,Feng N,Song N,Zhang W,Wu H,Zhang Z,Wang Z,Hua L. Evaluatingpossible predictors of prostate cancer to establish a scoring systemfor repeat biopsies in Chinese men.J Ultrasound Med.2011 Apr;30(4):503-8.1.547
53、Xu B,Li P,Niu X,Zhang X,Wang Z,Qin C,Li J,Jia Y,Wu H,Zhang W. A new method of chronic and recurrent seminal vesiculitis treatment.
J Endourol.2011 Nov;25(11):1815-8.
54、Feng N,Xu B,Tao J,Li P,Cheng G,Min Z,Mi Y,Wang M,Tong N,Tang J,Zhang Z,Wu H,Zhang W,Wang Z,Hua L. A miR-125b binding site polymorphism in bonemorphogenetic4 protein membrane receptor type IB gene and prostate cancer risk5in China.MolBiol Rep.2012 Jan;39(1):369-73.
55、Tao J, Wu D, Xu B, Qian W, Li P, Lu Q, Yin C, Zhang W. microRNA-133inhibitscellproliferation,migrationandinvasioninprostate cancercellsbytargetingtheepidermal growth factor receptor.Oncol Rep. 2012 Jun;27(6):1967-75.
56、Wu D, Tao J, Xu B, Li P, Lu Q, Zhang W. Downregulation of Dicer,a component of.the microRNA machinery,in bladder cancer.Mol Med Rep.2012 Mar;5(3):695-9.
57、Wang AX, Xu B,Tong N, Chen SQ, Yang Y, Zhang XW, Jiang H, Liu N, Liu J, Hu XN, Sha GZ,Chen M. miR-146a genecontributes to cancer susceptibility and that ethnicity, gender and smoking statusare risk factors.Genet Mol Res. 2012 Aug31;11(3):3051-62.1013
58、Xu B,Feng NH,TongN,Wang ZD,Zhang W,Wu HF,HuaLX. VEGF -460C>T polymorphism and cancer risk: ameta-analysis.Med Oncol.2010Dec;27(4):1031-6. doi: 10.1007/s12032-009-9329-2. Epub 2009 Oct 9.
59、LiXin Hua,Di Qiao, Bin Xu, Ning Han Feng, Gong Cheng, JieXiu Zhang , Ning Hong Song ,Wei Zhang, Jie Yang, JianGang Chen, YuanGeng Sui, HongFei Wu. Clinical and pathologicalcharacteristics of screen-detected versus clinically diagnosed prostate cancer in Nanjing, China. MedOncol (2011) 28:357–364
60、Ninghan Feng, Bin Xu, Jun Tao, Pengchao Li, Gong Cheng, Zhichao Min,
Yuanyuan Mi, MeilinWangm, Na Tong, Jialin Tang, Zhengdong Zhang, Hongfei Wu, Wei Zhang, Zengjun Wang, Lixin Hua. AmiR-125b binding site polymorphism in bone morphogenetic protein membranereceptor type IB gene and prostate cancer risk in China.Mol BiolRep (2012) 39:369–3731.889
61、Xu B,Li P,Niu X,Zhang X,Wang Z,Qin C,Li J,Jia Y,Wu H,Zhang W.A new method of chronic and recurrent seminal vesiculitis treatment.JEndourol.2011Nov;25(11):1815-8.